Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 26, 2018 16:01 ET | Source: Veru Inc.

Veru Announces Proposed Public Offering of Common Stock

MIAMI, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that it intends to offer and sell, subject to market...
September 12, 2018 08:00 ET | Source: Veru Inc.

Veru has Successful Pre-IND Meeting with FDA for VERU-111 Next Generation Novel Oral Anti-Tubulin Therapy for Metastatic Prostate Cancer

MIAMI, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, announced today that it has completed a Pre-Investigational New Drug...
August 30, 2018 08:00 ET | Source: Veru Inc.

Veru to Ring NASDAQ Closing Bell on August 31 to Kick Off National Prostate Cancer Awareness Month

MIAMI, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a urology and oncology biopharmaceutical company, today announced that that it has been invited by NASDAQ to ring the closing bell...
August 29, 2018 08:00 ET | Source: Veru Inc.

Veru Announces Additional Information Regarding its South Africa Female Condom Tender Award

MIAMI, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a urology and oncology biopharmaceutical company, today announced additional information regarding its recent award of 75% of a 120...
August 28, 2018 08:00 ET | Source: Veru Inc.

South Africa Female Condom Tender Award Additional Information

MIAMI, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a urology and oncology biopharmaceutical company, today announced additional information regarding its recent award of 75% of a 120...
August 27, 2018 08:00 ET | Source: Veru Inc.

Veru Awarded 75 Percent of South Africa Female Condom Tender

-- Overall Tender is for Up to 120 Million Female Condoms Over Three Years -- -- Awarded Up to 29.8 Million FC2 Female Condoms of 40 Million Total for First Year -- MIAMI, Aug. ...
August 14, 2018 06:30 ET | Source: Veru Inc.

Veru Reports Fiscal 2018 Third Quarter Financial Results

-- Investigational New Drug Application with the FDA Accepted for Phase 2 Study of Zuclomiphene -- -- VERU-111 Preclinical Efficacy Data in Four Different Cancers Presented at American Society of...
August 07, 2018 16:08 ET | Source: Veru Inc.

Veru to Report Fiscal 2018 Third-Quarter Financial Results, Host Conference Call on August 14th

MIAMI, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that on August 14, 2018, the company will report financial...
June 12, 2018 08:30 ET | Source: Veru Inc.

Veru to Start Phase 2 Trial to Evaluate Cis-Clomiphene Citrate to Treat Hot Flashes Caused by Advanced Prostate Cancer Therapy

-- Intellectual Property Position Strengthened; U.S. Patent Issued for VERU-944, Expiring 2035 -- -- VERU-944 Potentially First FDA-Approved Drug for this Indication -- MIAMI, June 12, 2018 (GLOBE...
May 30, 2018 08:30 ET | Source: Veru Inc.

Veru to Present at Jefferies 2018 Global Healthcare Conference on Wednesday, June 6th

MIAMI, May 30, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a urology and oncology biopharmaceutical company, today announced that the company’s Chairman, President and Chief Executive Officer,...